medigraphic.com
ISSN 1561-2937 (Print)

2021, Number 3

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2021; 27 (3)

COVID-19 Infection and Pulmonary Embolism

Alarcón CR, de la Torre FLM, Echevarría SLA

Language: Spanish
References: 23
Page: 1-3
PDF size: 228.5 Kb.


Text Extraction

No abstract.


REFERENCES

  1. World Health Organization. WHO Director General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet, publicado 11 Mar 2020]. World Health Organization [citado 8 May 2020]. Disponible en: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.

  2. Organización Panamericana de la Salud/Organización Mundial de la Salud. Actualización epidemiológica: Enfermedad del Coronavirus (COVID-19). 11 de diciembre del 2020, Washington, D.C.: OPS/OMS; 2020. Disponible en: https://bit.ly/2IJ0ifa.

  3. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-4.

  4. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi:10.1016/j.jacc.2020.04.031.

  5. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to d-dimer levels. Radiology. 2020;296:E189–91.

  6. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995–2002.

  7. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM,et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50.

  8. Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARSCoV-2. Int J Lab Hematol. 2020;42:19–20.

  9. Scudero F, Silverio A, Di Maio M, Pití A, Parodi G. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res.2021 Feb;198:34-39. doi: https://doi.org/10.16/j.thromres.20.20.11.017.

  10. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology. 2020;296:E186–8.

  11. Leonard-Lorant I, Delabranche X, Severac F, Helms J, Pauzet C, Collange O, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to d-dimer levels. Radiology. 2020;296:E189–91.

  12. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-90.

  13. De la Torre Fonseca LM. Lesión miocárdica del paciente con COVID-19. CorSalud [Internet].2020 vol.12, n.2 [citado 2021-02-15]; pp.171-183. Disponible en: http://scielo.sld.cu/scielo.php? script=sci_arttext&pid=S2078-71702020000200171&Ing=es&nrm=iso

  14. Rouhezamin MR, Haseli S. Diagnosing pulmonary thromboembolism in COVID-19: a stepwise clinical and imaging approach. Acad Radiol. 2020;27:896–7.

  15. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(2950):2973.

  16. Oudkerk M, Buller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. 2020. https ://doi.org/10.1148/radio l.20202 01629

  17. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.

  18. De Lorenzo A, Escobar S, Tibirica E. Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular and metabolic diseases. Nutr Metab Cardiovasc Dis. 2020;30:1401–2.

  19. Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: a Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017;69(6):815–26.

  20. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoia/Hypoxemia-Induced activation of the procoagulant pathas and the pathogenesis. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):09-35. Doi: 10.1161/01.atv.19.9.2020.

  21. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189:846–7.

  22. Todoran TM, Giri J, Barnes GD, et al. Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. J Thromb Thrombolysis. 2018;46(1):39-49.

  23. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–6.




2020     |     www.medigraphic.com